Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
15 hedge funds and large institutions have $1.8M invested in Evofem Biosciences, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.
7% more capital invested
Capital invested by funds: $1.68M → $1.8M (+$124K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less funds holding
Funds holding: 17 → 15 (-2)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$15K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.6K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$92 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$49.1K |
| 2 |
UBS AM
Chicago,
Illinois
|
-$45.3K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$18K |
| 4 |
Bank of New York Mellon
New York
|
-$10K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAD
1
Craig A. Drill
| $1.49M | – | – | – |
|
|
2
UBS AM
Chicago,
Illinois
| $105K | -$45.3K | -494 | -32% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $82K | +$12.6K | +138 | +20% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $40K | – | – | – |
|
5
Goldman Sachs
New York
| $20K | -$1.83K | -20 | -9% |
|
|
VKH
6
Virtu KCG Holdings
New York
| $19K | -$49.1K | -536 | -74% |
|
|
7
Citadel Advisors
Miami,
Florida
| $17K | +$15K | +164 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $7K | -$7.15K | -78 | -53% |
|
9
Morgan Stanley
New York
| $7K | -$183 | -2 | -3% |
|
|
BIT
10
BlackRock Institutional Trust
San Francisco,
California
| $6K | – | – | – |
|
|
WAS
11
WESPAC Advisors SoCal
Pasadena,
California
| $3.36K | – | – | – |
|
|
BA
12
BlackRock Advisors
Wilmington,
Delaware
| $2K | – | – | – |
|
|
BFA
13
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$92 | +1 | +8% |
|
|
ARTA
14
A.R.T. Advisors
New York
| – | -$18K | -212 | Closed |
|
|
15
Bank of New York Mellon
New York
| – | -$10K | -114 | Closed |
|
|
AIM
16
Acrospire Investment Management
Chicago,
Illinois
| – | -$1K | -14 | Closed |
|
EVFM Hedge Fund Activity: Q3 2016 in Review
15 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2016, worth a combined $1.8M — up 7.4% from $1.68M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of EVFM and 1 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $15K. The largest seller was Virtu KCG Holdings, cutting an estimated $49.1K.
- 15 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2016, down from 17 in Q2 2016.
- Funds reported $1.8M of Evofem Biosciences, Inc. Common Stock stock for Q3 2016, up 7.4% quarter-over-quarter.
- 1 fund opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2016 and 3 closed out, a net change of -2 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2016 was Citadel Advisors, an estimated $15K added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2016 was Virtu KCG Holdings, an estimated $49.1K sold.
Based on aggregated 13F filings for Q3 2016.